Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMRL3AB)

• Drug Name: Famotidine Drug Info
• Synonyms: Pepcid; famotidine; 76824-35-6; Pepcid AC; Pepcidine; Quamatel; Gastridin; Famodil; Dispromil; Pepdine; Digervin; Gaster; Fluxid; Pepdul; Pepcid RPD; Famulcer; Supertidine; Pepcidina; Fagastine; Whitidin; Farmotex; Peptifam; Ferotine; Dispronil; Tairal; Sigafam; Famtac; Durater; Yamarin; Pepzan; Famoxal; Evatin; Weimok; Pepdif; Fudone; Fanosin; Fanobel; Duovel; Fibonel; Fadine; Dipsin; Ganor; Fadin; Dinul; Fanox; Fadyn; Famox; Famo; Nu-Famotidine; Pepcidin Rapitab; Sedanium-R; Dibrit 40; Famotidinum [Latin]; PEPCID; Famotidina [Spanish]; Apogastine; Antodine; Bestidine; Amfamox; Blocacid; Brolin; Cepal; Confobos; Cronol; Cuantin; Famocid; Famodar; Famodin; Famodine; Famogard; Famonit; Famopsin; Famos; Famosan; Famotal; Famotep; Famotin; Famovane; Famowal; Gastridan; Gastrion; Gastro; Gastrodomina; Gastrofam; Gastropen; Gastrosidin; Hacip; Huberdina; Ingastri; Invigan; Lecedil; Logos; Mensoma; Midefam; Mosul; Motiax; Muclox; Neocidine; Nevofam; Notidin; Nulceran; Nulcerin; Panalba; Pepcidac; Pepcidin; Pepfamin; Peptan; Peptidin; Purifam; Quamtel; Renapepsa; Restadin; Rogasti; Rubacina; Tamin; Tipodex; Topcid; Ulcatif; Ulceprax; Ulcofam; Ulfagel; Ulfam; Ulfamid; Ulfinol; Ulgarine; Vagostal; FAMOTIDINE PRESERVATIVE FREE; FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER; Mylanta AR; PEPCID COMPLETE; PEPCID PRESERVATIVE FREE; PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER; Pepcid AC Gelcaps; PepcidRPD; F 6889; F0530; L 643341; MK 208; YM 11170; Apo-Famotidine; HS-0054; MK-208; Novo-Famotidine; Pepcid (TN); Pepcidine (TN); YM-11170; YM-1170; Famotidine [USAN:BAN:INN:JAN]; Propanimidamide, 3-[[[2-[aminoiminomethyl)amino]-4-thiazoyl]methyl]thio]-N-(aminosulfonyl); N'-(Aminosulfonyl)-3-([2-(diaminomethyleneamino)-4-thiazolyl]methylthio)propanamidine; (1-Amino-3-(((2-((diaminomethylene)amino)-4-thiazolyl)methyl)thio)propylidene)sulfamide; (1Z)-3-[({2-[(diaminomethylidene)amino]-1,3-thiazol-4-yl}methyl)sulfanyl]-N'-sulfamoylpropanimidamide; (1Z)-N'-(aminosulfonyl)-3-[({2-[(diaminomethylidene)amino]-1,3-thiazol-4-yl}methyl)thio]propanimidamide; 3-(2-Guanidinothiazol-4-ylmethylthio)-N1-sulfamoylpropionamide; 3-[({2-[(diaminomethylidene)amino]-1,3-thiazol-4-yl}methyl)sulfanyl]-N-sulfamoylpropanimidamide; 3-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]-N'-sulfamoylpro; 3-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]-N'-sulfamoylpropanimidamide

Indication

Disease Entry	ICD 11	Status	REF
Gastric ulcer	DA60	Approved	[1]
Gastrinoma	2C10.1	Approved	[1]
Peptic esophagitis		Approved	[1]
Peptic ulcer	DA61	Approved	[2]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 3	[3]

• Therapeutic Class: Antiulcer Agents
• Cross-matching ID:
  PubChem CID: 5702160
  ChEBI ID: CHEBI:4975
  CAS Number: CAS 76824-35-6
  TTD Drug ID: DMRL3AB
  VARIDT Drug ID: DR00278
  INTEDE Drug ID: DR0680
  ACDINA Drug ID: D00518

Molecule-Related Drug Atlas

Drug(s) Targeting Histamine H2 receptor (H2R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ranitidine	DM0GUSX	Gastric ulcer	DA60	Approved	[14]
Cimetidine	DMH61ZB	Acid-reflux disorder	DA22	Approved	[4]
Nizatidine	DMGFV3Z	Acid-reflux disorder	DA22	Approved	[15]
Betazole	DMUFGAY	Gastric secretory disorder	DD90	Approved	[16]
Ebrotidine	DMV5KR3	Duodenal ulcer	DA63	Withdrawn from market	[17]
Pibutidine	DMXSTRM	Ulcerative colitis	DD71	Discontinued in Phase 3	[18]
Osutidine	DMN7TL8	Duodenal ulcer	DA63	Discontinued in Phase 3	[19]
KU-1257	DMZMFX6	Duodenal ulcer	DA63	Discontinued in Phase 3	[20]
Lavoltidine	DMTY5VE	Gastroesophageal reflux disease	DA22.Z	Discontinued in Phase 2	[21]
IGN-2098	DMU4N1O	Duodenal ulcer	DA63	Discontinued in Phase 2	[22]

Drug(s) Transported By Organic cation transporter 2 (SLC22A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[23]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[24]
Oxaliplatin	DMQNWRD	Adenocarcinoma	2D40	Approved	[25]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[26]
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[27]
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[28]
Ergotidine	DM78IME	Osteoarthritis	FA00-FA05	Approved	[29]
Metformin	DM89QE1	Colorectal carcinoma		Approved	[30]
Clonidine	DM6RZ9Q	Attention deficit hyperactivity disorder	6A05.Z	Approved	[28]
Ranitidine	DM0GUSX	Gastric ulcer	DA60	Approved	[6]

Drug(s) Transported By Organic anion transporter 1 (SLC22A6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amoxicillin	DMUYNEI	Acute otitis media	AB00	Approved	[31]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[32]
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[33]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[34]
Aciclovir	DMYLOVR	Genital herpes	1A94	Approved	[34]
Ganciclovir	DM1MBYQ	Cytomegalovirus infection	1D82	Approved	[34]
Cefazolin	DMPDYFR	Bacteremia	1A73	Approved	[35]
Olmesartan medoxomil	DMWBHRY	High blood pressure	BA00	Approved	[36]
Zalcitabine	DMH7MUV	Human immunodeficiency virus infection	1C62	Approved	[37]
FLUORESCEIN	DMQTFAO	Ocular disease	1F00.1Z	Approved	[38]

Drug(s) Transported By Organic anion transporter 3 (SLC22A8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[39]
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[33]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[34]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[40]
Pravastatin	DM6A0X7	Adult acute monocytic leukemia		Approved	[41]
L-Tryptophan	DMIBH7M	Depression	6A70-6A7Z	Approved	[42]
Mercaptopurine	DMTM2IK	Acute lymphoblastic leukaemia	2A85	Approved	[43]
PITAVASTATIN CALCIUM	DM1UJO0	Dyslipidemia	5C80-5C81	Approved	[44]
Rosuvastatin	DMMIQ7G	Arteriosclerosis	BD40	Approved	[45]
Cilostazol	DMZMSCT	Intermittent claudication	BD40.00	Approved	[46]
Valsartan	DMREUQ6	Chronic heart failure	BD1Z	Approved	[64]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[65]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[66]
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[40]
Ranitidine	DM0GUSX	Gastric ulcer	DA60	Approved	[6]
Cimetidine	DMH61ZB	Acid-reflux disorder	DA22	Approved	[6]
Cefdinir	DMJ7A0H	Bacterial infection	1A00-1C4Z	Approved	[67]
Cefaclor	DMJXDGC	Bacterial infection	1A00-1C4Z	Approved	[67]
Tetracycline	DMZA017	Acne vulgaris	ED80	Approved	[68]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[69]

Drug(s) Metabolized By Mephenytoin 4-hydroxylase (CYP2C19)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amoxicillin	DMUYNEI	Acute otitis media	AB00	Approved	[47]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[48]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[49]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[50]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[51]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[52]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[53]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[54]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[55]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[56]

Drug(s) Affected By Solute carrier family 22 member 2 (SLC22A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[57]
Cimetidine	DMH61ZB	Acid-reflux disorder	DA22	Approved	[58]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[58]
Ranitidine	DM0GUSX	Gastric ulcer	DA60	Approved	[6]
Lamivudine	DMI347A	Chronic HBV infection	1E51.0Z	Approved	[59]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[60]
Trospium chloride	DM32XZT	Discovery agent	N.A.	Approved	[61]
Phenoxybenzamine	DM8KSQH	Malignant essential hypertension	BA00	Approved	[62]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[63]
Indomethacin	DMSC4A7	Bursitis		Approved	[60]

Drug(s) Affected By Solute carrier family 22 member 3 (SLC22A3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Epinephrine	DM3KJBC	Acute asthma	CA23	Approved	[70]
Ergotidine	DM78IME	Osteoarthritis	FA00-FA05	Approved	[70]
Norepinephrine	DMOUC09	Alopecia	ED70	Approved	[70]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[71]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[72]
Phenoxybenzamine	DM8KSQH	Malignant essential hypertension	BA00	Approved	[62]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[73]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[63]
Enzalutamide	DMGL19D	Prostate cancer	2C82.0	Approved	[74]
Mifepristone	DMGZQEF	Cushing disease	5A70	Approved	[75]

Drug(s) Affected By Transmembrane protease serine 2 (TMPRSS2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tolbutamide	DM02AWV	Advanced cancer	2A00-2F9Z	Approved	[76]
Diazepam	DM08E9O	Alcohol withdrawal		Approved	[76]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[77]
Selenium	DM25CGV	N. A.	N. A.	Approved	[78]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[76]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[76]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[76]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[76]
Omeprazole	DM471KJ	Cystic fibrosis	CA25	Approved	[76]
Fluphenazine	DMIT8LX	Psychotic disorder	6A20-6A25	Approved	[76]

Drug(s) Affected By Prolactin (PRL)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[79]
Ranitidine	DM0GUSX	Gastric ulcer	DA60	Approved	[80]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[81]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[82]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[83]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[84]
Naloxone	DM3FXMA	Narcotic depression	6A7Z	Approved	[85]
Aripiprazole	DM3NUMH	Bipolar I disorder		Approved	[86]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[87]
Penicillamine	DM40EF6	Cystinuria	5C60.2	Approved	[88]

Drug(s) Affected By Gastrin (GAST)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ranitidine	DM0GUSX	Gastric ulcer	DA60	Approved	[10]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[89]
Terbutaline	DMD4381	Asthma	CA23	Approved	[90]
Cimetidine	DMH61ZB	Acid-reflux disorder	DA22	Approved	[10]
Sodium lauryl sulfate	DMLJ634	Constipation	DD91.1	Approved	[91]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[92]
Lansoprazole	DMXYLQ3	Gastric ulcer	DA60	Approved	[93]
DTI-015	DMXZRW0	Brain cancer	2A00	Approved	[94]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[11]
Resveratrol	DM3RWXL	Giant cell arteritis	4A44.2	Phase 3	[95]

Drug(s) Affected By HLA class I histocompatibility antigen, alpha chain E (HLA-E)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ofloxacin	DM0VQN3	Acute gonococcal cervicitis		Approved	[12]
Clindamycin	DM15HL8	Acne vulgaris	ED80	Approved	[12]
Selenium	DM25CGV	N. A.	N. A.	Approved	[78]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[12]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[12]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[96]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[97]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[98]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[12]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[99]

Drug(s) Affected By Serine/threonine-protein kinase B-raf (BRAF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[100]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[97]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[101]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[102]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[103]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[104]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[105]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[106]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[107]
Gemcitabine	DMSE3I7	Anterior urethra cancer		Approved	[108]

Drug(s) Affected By HLA class II histocompatibility antigen, DM beta chain (HLA-DMB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Topiramate	DM82Z30	Alcohol dependence	6C40.2	Approved	[12]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[109]
Valdecoxib	DMAY7H4	Osteoarthritis	FA00-FA05	Approved	[12]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[110]
Ethosuximide	DMDZ9LT	Epilepsy	8A60-8A68	Approved	[12]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[111]
Vancomycin	DM3JFIH	Bacteremia	1A73	Approved	[12]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[112]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[113]
Bortezomib	DMNO38U	Leukemia		Approved	[114]

Drug(s) Affected By Catenin beta-1 (CTNNB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[115]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[116]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[117]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[118]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[119]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[120]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[121]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[122]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[123]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[124]

Drug(s) Affected By Fibroblast growth factor 21 (FGF21)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[73]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[89]
Fenofibrate	DMFKXDY	Coronary atherosclerosis		Approved	[125]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[126]
Pioglitazone	DMKJ485	Amyotrophic lateral sclerosis	8B60.0	Approved	[126]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[127]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[128]
Lansoprazole	DMXYLQ3	Gastric ulcer	DA60	Approved	[9]
Bezafibrate	DMZDCS0	Hypercholesterolaemia	5C80.0	Approved	[125]
Resveratrol	DM3RWXL	Giant cell arteritis	4A44.2	Phase 3	[129]

Drug(s) Affected By Interleukin-3 (IL3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[83]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[130]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[130]
Menthol	DMG2KW7	Back pain	ME84.Z	Approved	[131]
Betamethasone Valerate	DMMIAXO	Dermatological disease	DA24.Y	Approved	[132]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[133]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[134]
Tacrolimus	DMZ7XNQ	Graft-versus-host disease	4B24	Approved	[132]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[11]
Cytarabine	DMZD5QR	Acute lymphoblastic leukaemia	2A85	Approved	[11]

Drug(s) Affected By Granulocyte-macrophage colony-stimulating factor (CSF2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[135]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[136]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[137]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[138]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[139]
Ergotidine	DM78IME	Osteoarthritis	FA00-FA05	Approved	[140]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[99]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[141]
Acetylcholine	DMDF79Z	Cataract	9B10	Approved	[142]
Docetaxel	DMDI269	Advanced cancer	2A00-2F9Z	Approved	[143]

Drug(s) Affected By Solute carrier family 22 member 1 (SLC22A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Phenoxybenzamine	DM8KSQH	Malignant essential hypertension	BA00	Approved	[62]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[57]
Trospium chloride	DM32XZT	Discovery agent	N.A.	Approved	[61]
Ranitidine	DM0GUSX	Gastric ulcer	DA60	Approved	[144]
Lamivudine	DMI347A	Chronic HBV infection	1E51.0Z	Approved	[59]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[60]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[145]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[146]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[147]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[60]

Drug(s) Affected By Thiamine transporter 2 (SLC19A3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[77]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[72]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[148]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[149]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[73]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[104]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[150]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[151]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[77]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[152]

Drug(s) Affected By Granulocyte colony-stimulating factor receptor (CSF3R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[83]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[72]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[153]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[154]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[109]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[103]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[89]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[155]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[128]
Coprexa	DMA0WEK	Neurological disorder	6B60	Phase 3	[156]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Histamine H2 receptor (H2R)	TTQHJ1K	HRH2_HUMAN	Antagonist	[4]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Organic anion transporter 1 (SLC22A6)	DTQ23VB	S22A6_HUMAN	Substrate	[5]
Organic cation transporter 2 (SLC22A2)	DT9IDPW	S22A2_HUMAN	Substrate	[6]
Organic anion transporter 3 (SLC22A8)	DTVP67E	S22A8_HUMAN	Substrate	[6]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Mephenytoin 4-hydroxylase (CYP2C19) Main DME	DEGTFWK	CP2CJ_HUMAN	Substrate	[7]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Catenin beta-1 (CTNNB1)	OTZ932A3	CTNB1_HUMAN	Gene/Protein Processing	[8]
Fibroblast growth factor 21 (FGF21)	OT3RXVRD	FGF21_HUMAN	Gene/Protein Processing	[9]
Gastrin (GAST)	OTD0IP9N	GAST_HUMAN	Gene/Protein Processing	[10]
Granulocyte colony-stimulating factor receptor (CSF3R)	OTXRAY6X	CSF3R_HUMAN	Drug Response	[11]
Granulocyte-macrophage colony-stimulating factor (CSF2)	OT1M7D28	CSF2_HUMAN	Drug Response	[11]
HLA class I histocompatibility antigen, alpha chain E (HLA-E)	OTX1CTFB	HLAE_HUMAN	Gene/Protein Processing	[12]
HLA class II histocompatibility antigen, DM beta chain (HLA-DMB)	OT17HGXJ	DMB_HUMAN	Gene/Protein Processing	[12]
Interleukin-3 (IL3)	OT0CQ35N	IL3_HUMAN	Drug Response	[11]
Organic anion transporter 3 (SLC22A8)	OT8BY933	S22A8_HUMAN	Regulation of Drug Effects	[5]
Prolactin (PRL)	OTWFQGX7	PRL_HUMAN	Gene/Protein Processing	[13]

References

• [1] Famotidine FDA Label
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7074).
• [3] ClinicalTrials.gov (NCT04370262) Multi-site Adaptive Trials Using Hydroxycholoroquine for COVID-19. U.S. National Institutes of Health.
• [4] Histamine H1 and H2 receptor antagonists accelerate skin barrier repair and prevent epidermal hyperplasia induced by barrier disruption in a dry environment. J Invest Dermatol. 2001 Feb;116(2):261-5.
• [5] Different transport properties between famotidine and cimetidine by human renal organic ion transporters (SLC22A). Eur J Pharmacol. 2004 Oct 25;503(1-3):25-30.
• [6] A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther. 2005 Oct;315(1):337-45.
• [7] Initial 48-hour acid inhibition by intravenous infusion of omeprazole, famotidine, or both in relation to cytochrome P450 2C19 genotype status. Clin Pharmacol Ther. 2006 Nov;80(5):539-48.
• [8] Famotidine has a neuroprotective effect on MK-801 induced toxicity via the Akt/GSK-3/-catenin signaling pathway in the SH-SY5Y cell line. Chem Biol Interact. 2019 Dec 1;314:108823. doi: 10.1016/j.cbi.2019.108823. Epub 2019 Sep 26.
• [9] Increased immunoreactivity and concentration of basic fibroblast growth factor in lansoprazole-treated gastric mucosa. J Clin Gastroenterol. 1995;21 Suppl 1:S24-9.
• [10] Effects of three H2-receptor antagonists (cimetidine, famotidine, ranitidine) on serum gastrin level. Int J Clin Pharmacol Res. 2002;22(2):29-35.
• [11] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [12] Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. Chem Res Toxicol. 2015 May 18;28(5):927-34. doi: 10.1021/tx5005248. Epub 2015 Apr 3.
• [13] Hyperprolactinaemia during famotidine therapy. Lancet. 1993 Oct 2;342(8875):868. doi: 10.1016/0140-6736(93)92729-d.
• [14] Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51.
• [15] Does the use of nizatidine, as a pro-kinetic agent, improve gastric emptying in patients post-oesophagectomy J Gastrointest Surg. 2009 Mar;13(3):432-7.
• [16] Effect of nizatidine and cimetidine on betazole-stimulated gastric secretion of normal subjects: comparison of effects on acid, water, and pepsin. Am J Gastroenterol. 1988 Jan;83(1):32-6.
• [17] Histamine H2-receptor antagonist action of ebrotidine. Effects on gastric acid secretion, gastrin levels and NSAID-induced gastrotoxicity in the rat. Arzneimittelforschung. 1997 Apr;47(4A):439-46.
• [18] Comparative pharmacology of epibatidine: a potent agonist for neuronal nicotinic acetylcholine receptors. Mol Pharmacol. 1995 Oct;48(4):774-82.
• [19] Effects of osutidine (T-593) and its enantiomers on gastric mucosal hemodynamics and mucosal integrity in anesthetized rats. Arzneimittelforschung. 2001 Jan;51(1):46-50.
• [20] Pharmacological profiles of the new histamine H2-receptor antagonist N-ethyl-N'-[3-[3-(piperidinomethyl)phenoxy] propyl] urea. Arzneimittelforschung. 1993 Feb;43(2):129-33.
• [21] New and Future Drug Development for Gastroesophageal Reflux Disease. J Neurogastroenterol Motil. 2014 January; 20(1): 6-16.
• [22] Effects of IGN-2098, a new histamine H2-receptor antagonist, on gastric secretion and gastric and duodenal lesions induced in rats. Comparison with roxatidine. Nihon Yakurigaku Zasshi. 1992 Mar;99(3):167-80.
• [23] Are organic cation transporters capable of transporting prostaglandins? Naunyn Schmiedebergs Arch Pharmacol. 2005 Aug;372(2):125-30.
• [24] Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol. 2005 Dec;167(6):1477-84.
• [25] Relevance of copper transporter 1 and organic cation transporters 1-3 for oxaliplatin uptake and drug resistance in colorectal cancer cells. Metallomics. 2018 Mar 1;10(3):414-425.
• [26] Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol. 1997 Jul;16(7):871-81.
• [27] Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology. 2006 Jun;50(8):941-52.
• [28] Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145.
• [29] The organic cation transporters (OCT1, OCT2, EMT) and the plasma membrane monoamine transporter (PMAT) show differential distribution and cyclic expression pattern in human endometrium and early pregnancy decidua. Mol Reprod Dev. 2007 Oct;74(10):1303-11.
• [30] Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet. 2005 Oct;20(5):379-86.
• [31] The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies. Drug Metab Dispos. 2002 Jan;30(1):13-9.
• [32] Transport of aminopterin by human organic anion transporters hOAT1 and hOAT3: Comparison with methotrexate. Drug Metab Pharmacokinet. 2010;25(2):163-9.
• [33] Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J Pharmacol Exp Ther. 2002 Apr;301(1):293-8.
• [34] Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002 Mar;300(3):918-24.
• [35] Expression levels of renal organic anion transporters (OATs) and their correlation with anionic drug excretion in patients with renal diseases. Pharm Res. 2004 Jan;21(1):61-7.
• [36] Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor. Drug Metab Dispos. 2007 Dec;35(12):2166-76.
• [37] Interaction of zalcitabine with human organic anion transporter 1. Pharmazie. 2006 May;61(5):491-2.
• [38] Apical expression or expression in a non polarized cell of hOAT1 inverses regulation by epidermal growth factor (EGF) as compared to basolateral hOAT1. Cell Physiol Biochem. 2004;14(3):177-86.
• [39] Methotrexate-loxoprofen interaction: involvement of human organic anion transporters hOAT1 and hOAT3. Drug Metab Pharmacokinet. 2004 Oct;19(5):369-74.
• [40] Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol. 2001 May;59(5):1277-86.
• [41] Prediction of the overall renal tubular secretion and hepatic clearance of anionic drugs and a renal drug-drug interaction involving organic anion transporter 3 in humans by in vitro uptake experiments. Drug Metab Dispos. 2011 Jun;39(6):1031-8.
• [42] Murine renal organic anion transporters mOAT1 and mOAT3 facilitate the transport of neuroactive tryptophan metabolites. Am J Physiol Cell Physiol. 2005 Nov;289(5):C1075-84.
• [43] Organic anion transporter 3 is involved in the brain-to-blood efflux transport of thiopurine nucleobase analogs. J Neurochem. 2004 Aug;90(4):931-41.
• [44] Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol. 2005 Oct;57(10):1305-11.
• [45] The contribution of organic anion transporters OAT1 and OAT3 to the renal uptake of rosuvastatin. J Pharmacol Exp Ther. 2007 Sep;322(3):1221-7.
• [46] Aspirin and probenecid inhibit organic anion transporter 3-mediated renal uptake of cilostazol and probenecid induces metabolism of cilostazol in the rat. Drug Metab Dispos. 2014 Jun;42(6):996-1007.
• [47] High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
• [48] Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
• [49] Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
• [50] CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
• [51] Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
• [52] Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
• [53] Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
• [54] A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
• [55] Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
• [56] Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
• [57] Involvement of aryl hydrocarbon receptor in the cytotoxicity of corannulene and its derivatives. Toxicol Lett. 2020 Mar 15;321:114-121. doi: 10.1016/j.toxlet.2019.12.012. Epub 2019 Dec 9.
• [58] Ameliorative effects of SLC22A2 gene polymorphism 808 G/T and cimetidine on cisplatin-induced nephrotoxicity in Chinese cancer patients. Food Chem Toxicol. 2012 Jul;50(7):2289-93. doi: 10.1016/j.fct.2012.03.077. Epub 2012 Apr 16.
• [59] Transport of lamivudine [(-)-beta-L-2',3'-dideoxy-3'-thiacytidine] and high-affinity interaction of nucleoside reverse transcriptase inhibitors with human organic cation transporters 1, 2, and 3. J Pharmacol Exp Ther. 2009 Apr;329(1):252-61. doi: 10.1124/jpet.108.146225. Epub 2009 Jan 13.
• [60] Interactions of human organic anion transporters and human organic cation transporters with nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther. 2002 Nov;303(2):534-9.
• [61] Expression of drug transporters and drug metabolizing enzymes in the bladder urothelium in man and affinity of the bladder spasmolytic trospium chloride to transporters likely involved in its pharmacokinetics. Mol Pharm. 2015 Jan 5;12(1):171-8.
• [62] Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol. 2002 Jul;136(6):829-36.
• [63] Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
• [64] Uric acid accumulation in the kidney triggers mast cell degranulation and aggravates renal oxidative stress. Toxicology. 2023 Jan 1;483:153387. doi: 10.1016/j.tox.2022.153387. Epub 2022 Dec 1.
• [65] P-gp, MRP2 and OAT1/OAT3 mediate the drug-drug interaction between resveratrol and methotrexate. Toxicol Appl Pharmacol. 2016 Sep 1;306:27-35. doi: 10.1016/j.taap.2016.06.030. Epub 2016 Jul 1.
• [66] Intracellular concentrations determine the cytotoxicity of adefovir, cidofovir and tenofovir. Toxicol In Vitro. 2015 Feb;29(1):251-8. doi: 10.1016/j.tiv.2014.10.019.
• [67] Human organic anion transporter hOAT3 is a potent transporter of cephalosporin antibiotics, in comparison with hOAT1. Biochem Pharmacol. 2005 Oct 1;70(7):1104-13.
• [68] Human organic anion transporters mediate the transport of tetracycline. Jpn J Pharmacol. 2002 Jan;88(1):69-76.
• [69] Potent Inhibitors of Organic Anion Transporters 1 and 3 From Natural Compounds and Their Protective Effect on Aristolochic Acid Nephropathy. Toxicol Sci. 2020 Jun 1;175(2):279-291. doi: 10.1093/toxsci/kfaa033.
• [70] Selective transport of monoamine neurotransmitters by human plasma membrane monoamine transporter and organic cation transporter 3. J Pharmacol Exp Ther. 2010 Dec;335(3):743-53. doi: 10.1124/jpet.110.170142. Epub 2010 Sep 21.
• [71] Time series analysis of oxidative stress response patterns in HepG2: a toxicogenomics approach. Toxicology. 2013 Apr 5;306:24-34.
• [72] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [73] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [74] LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A. 2018 May 1;115(18):E4179-E4188.
• [75] Mifepristone induced progesterone withdrawal reveals novel regulatory pathways in human endometrium. Mol Hum Reprod. 2007 Sep;13(9):641-54.
• [76] Effect of common medications on the expression of SARS-CoV-2 entry receptors in liver tissue. Arch Toxicol. 2020 Dec;94(12):4037-4041. doi: 10.1007/s00204-020-02869-1. Epub 2020 Aug 17.
• [77] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [78] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [79] Verapamil-induced hyperprolactinemia complicated by a pituitary incidentaloma. Ann Pharmacother. 1995 Oct;29(10):999-1001. doi: 10.1177/106002809502901009.
• [80] [Impotence and gynecomastia secondary to hyperprolactinemia induced by ranitidine]. Therapie. 1994 Jul-Aug;49(4):361-2.
• [81] Differential effects of estrogen receptor antagonists on pituitary lactotroph proliferation and prolactin release. Mol Cell Endocrinol. 2005 Jul 15;239(1-2):27-36. doi: 10.1016/j.mce.2005.04.008.
• [82] Cholinergic modulation of the cerebral metabolic response to citalopram in Alzheimer's disease. Brain. 2009 Feb;132(Pt 2):392-401. doi: 10.1093/brain/awn326. Epub 2009 Jan 19.
• [83] The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
• [84] The effect of thioridazine on prolactinoma growth in a schizophrenic man: case report. Gen Hosp Psychiatry. 1985 Oct;7(4):364-6. doi: 10.1016/0163-8343(85)90053-2.
• [85] Influence of naloxone on muscle sympathetic nerve activity, systemic and calf haemodynamics and ambulatory blood pressure after exercise in mild essential hypertension. J Hypertens. 1995 Apr;13(4):447-61.
• [86] The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials. J Affect Disord. 2009 May;115(1-2):18-26. doi: 10.1016/j.jad.2008.12.017. Epub 2009 Feb 23.
• [87] Serum prolactin levels among outpatients with major depressive disorder during the acute phase of treatment with fluoxetine. J Clin Psychiatry. 2006 Jun;67(6):952-7. doi: 10.4088/jcp.v67n0612.
• [88] Massive breast enlargement in a patient receiving D-penicillamine for systemic sclerosis. J Rheumatol. 1985 Oct;12(5):990-1.
• [89] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [90] L-type calcium channels regulate gastrin release from human antral G cells. Am J Physiol. 1997 Aug;273(2 Pt 1):G281-8. doi: 10.1152/ajpgi.1997.273.2.G281.
• [91] CXCL14 downregulation in human keratinocytes is a potential biomarker for a novel in vitro skin sensitization test. Toxicol Appl Pharmacol. 2020 Jan 1;386:114828. doi: 10.1016/j.taap.2019.114828. Epub 2019 Nov 14.
• [92] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [93] Influence of lansoprazole on intragastric 24-hour pH, meal-stimulated gastric acid secretion, and concentrations of gastrointestinal hormones and enzymes in serum and gastric juice in healthy volunteers. Digestion. 1995;56(2):137-44. doi: 10.1159/000201233.
• [94] Gene expression profile induced by BCNU in human glioma cell lines with differential MGMT expression. J Neurooncol. 2005 Jul;73(3):189-98.
• [95] Grape resveratrol increases serum adiponectin and downregulates inflammatory genes in peripheral blood mononuclear cells: a triple-blind, placebo-controlled, one-year clinical trial in patients with stable coronary artery disease. Cardiovasc Drugs Ther. 2013 Feb;27(1):37-48. doi: 10.1007/s10557-012-6427-8.
• [96] Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
• [97] Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
• [98] Global effects of inorganic arsenic on gene expression profile in human macrophages. Mol Immunol. 2009 Feb;46(4):649-56.
• [99] The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
• [100] Effect of all-trans retinoic acid on sodium/iodide symporter expression, radioiodine uptake and gene expression profiles in a human anaplastic thyroid carcinoma cell line. Nucl Med Biol. 2006 Oct;33(7):875-82. doi: 10.1016/j.nucmedbio.2006.07.004.
• [101] A comprehensive analysis of Wnt/beta-catenin signaling pathway-related genes and crosstalk pathways in the treatment of As2O3 in renal cancer. Ren Fail. 2018 Nov;40(1):331-339.
• [102] Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
• [103] Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
• [104] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [105] Computational discovery of niclosamide ethanolamine, a repurposed drug candidate that reduces growth of hepatocellular carcinoma cells initro and in mice by inhibiting cell division cycle 37 signaling. Gastroenterology. 2017 Jun;152(8):2022-2036.
• [106] Drug-induced endoplasmic reticulum and oxidative stress responses independently sensitize toward TNF-mediated hepatotoxicity. Toxicol Sci. 2014 Jul;140(1):144-59. doi: 10.1093/toxsci/kfu072. Epub 2014 Apr 20.
• [107] Rap1/B-Raf signaling is activated in neuroendocrine tumors of the digestive tract and Raf kinase inhibition constitutes a putative therapeutic target. Neuroendocrinology. 2007;85(1):45-53. doi: 10.1159/000100508. Epub 2007 Mar 5.
• [108] A fine-needle aspirate-based vulnerability assay identifies polo-like kinase 1 as a mediator of gemcitabine resistance in pancreatic cancer. Mol Cancer Ther. 2010 Feb;9(2):311-8. doi: 10.1158/1535-7163.MCT-09-0693. Epub 2010 Jan 26.
• [109] Identification of vitamin D3 target genes in human breast cancer tissue. J Steroid Biochem Mol Biol. 2016 Nov;164:90-97.
• [110] Stem cell transcriptome responses and corresponding biomarkers that indicate the transition from adaptive responses to cytotoxicity. Chem Res Toxicol. 2017 Apr 17;30(4):905-922.
• [111] Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
• [112] Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
• [113] Chromosomal radiosensitivity in two cell lineages derived from clinically radiosensitive cancer patients. Clin Cancer Res. 2005 Sep 1;11(17):6352-8. doi: 10.1158/1078-0432.CCR-04-1931.
• [114] The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. Exp Hematol. 2011 Jan;39(1):55-65.
• [115] Inhibition of autophagic flux differently modulates cannabidiol-induced death in 2D and 3D glioblastoma cell cultures. Sci Rep. 2020 Feb 14;10(1):2687. doi: 10.1038/s41598-020-59468-4.
• [116] Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
• [117] Sulindac suppresses beta-catenin expression in human cancer cells. Eur J Pharmacol. 2008 Mar 31;583(1):26-31. doi: 10.1016/j.ejphar.2007.12.034. Epub 2008 Feb 5.
• [118] Multifaceted preventive effects of single agent quercetin on a human prostate adenocarcinoma cell line (PC-3): implications for nutritional transcriptomics and multi-target therapy. Med Oncol. 2011 Dec;28(4):1395-404. doi: 10.1007/s12032-010-9603-3. Epub 2010 Jul 2.
• [119] Multifaceted suppression of aggressive behavior of thyroid carcinoma by all-trans retinoic acid induced re-differentiation. Mol Cell Endocrinol. 2012 Jan 2;348(1):260-9. doi: 10.1016/j.mce.2011.09.002. Epub 2011 Sep 6.
• [120] Arsenic trioxide and 2-methoxyestradiol reduce beta-catenin accumulation after proteasome inhibition and enhance the sensitivity of myeloma cells to Bortezomib. Leuk Res. 2008 Nov;32(11):1674-83. doi: 10.1016/j.leukres.2008.03.039. Epub 2008 May 15.
• [121] Effect of aspirin on the Wnt/beta-catenin pathway is mediated via protein phosphatase 2A. Oncogene. 2006 Oct 19;25(49):6447-56. doi: 10.1038/sj.onc.1209658. Epub 2006 Jul 31.
• [122] Benzene metabolite hydroquinone induces apoptosis of bone marrow mononuclear cells through inhibition of -catenin signaling. Toxicol In Vitro. 2018 Feb;46:361-369. doi: 10.1016/j.tiv.2017.08.018. Epub 2017 Sep 5.
• [123] Anti-androgen 2-hydroxyflutamide modulates cadherin, catenin and androgen receptor phosphorylation in androgen-sensitive LNCaP and androgen-independent PC3 prostate cancer cell lines acting via PI3K/Akt and MAPK/ERK1/2 pathways. Toxicol In Vitro. 2017 Apr;40:324-335. doi: 10.1016/j.tiv.2017.01.019. Epub 2017 Feb 2.
• [124] Anthelmintic Niclosamide Disrupts the Interplay of p65 and FOXM1/-catenin and Eradicates Leukemia Stem Cells in Chronic Myelogenous Leukemia. Clin Cancer Res. 2017 Feb 1;23(3):789-803. doi: 10.1158/1078-0432.CCR-16-0226. Epub 2016 Aug 4.
• [125] Sodium butyrate stimulates expression of fibroblast growth factor 21 in liver by inhibition of histone deacetylase 3. Diabetes. 2012 Apr;61(4):797-806. doi: 10.2337/db11-0846. Epub 2012 Feb 14.
• [126] Thiazolidinediones are potent inducers of fibroblast growth factor 21 expression in the liver. Biol Pharm Bull. 2011;34(7):1120-1. doi: 10.1248/bpb.34.1120.
• [127] Activation of GR but not PXR by dexamethasone attenuated acetaminophen hepatotoxicities via Fgf21 induction. Toxicology. 2017 Mar 1;378:95-106. doi: 10.1016/j.tox.2017.01.009. Epub 2017 Jan 11.
• [128] Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: application to acetaminophen injury. Toxicol Appl Pharmacol. 2012 Mar 15;259(3):270-80.
• [129] Hepatic SIRT1 attenuates hepatic steatosis and controls energy balance in mice by inducing fibroblast growth factor 21. Gastroenterology. 2014 Feb;146(2):539-49.e7. doi: 10.1053/j.gastro.2013.10.059. Epub 2013 Nov 1.
• [130] Alcohol and Cannabinoids Differentially Affect HIV Infection and Function of Human Monocyte-Derived Dendritic Cells (MDDC). Front Microbiol. 2015 Dec 22;6:1452. doi: 10.3389/fmicb.2015.01452. eCollection 2015.
• [131] Repurposing L-menthol for systems medicine and cancer therapeutics? L-menthol induces apoptosis through caspase 10 and by suppressing HSP90. OMICS. 2016 Jan;20(1):53-64.
• [132] Tacrolimus suppressed the production of cytokines involved in atopic dermatitis by direct stimulation of human PBMC system. (Comparison with steroids). Int Immunopharmacol. 2001 Jun;1(6):1219-26. doi: 10.1016/s1567-5769(01)00059-5.
• [133] Effects of theophylline, dexamethasone and salbutamol on cytokine gene expression in human peripheral blood CD4+ T-cells. Eur Respir J. 1999 Nov;14(5):1106-12. doi: 10.1183/09031936.99.14511069.
• [134] Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Clin Pharmacol Ther. 2016 Apr;99(4):432-41.
• [135] Cytokine mRNA profiles in cultured human skin component cells exposed to various chemicals: a simulation model of epicutaneous stimuli induced by skin barrier perturbation in comparison with that due to exposure to haptens or irritant. J Dermatol Sci. 2001 Jun;26(2):85-93. doi: 10.1016/s0923-1811(00)00165-1.
• [136] Effects of luteolin, quercetin and baicalein on immunoglobulin E-mediated mediator release from human cultured mast cells. Clin Exp Allergy. 2000 Apr;30(4):501-8. doi: 10.1046/j.1365-2222.2000.00768.x.
• [137] Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model. Toxicol In Vitro. 2009 Oct;23(7):1387-95.
• [138] Altered cytokine profiles of human retinal pigment epithelium: oxidant injury and replicative senescence. Mol Vis. 2013;19:718-28. Epub 2013 Mar 21.
• [139] Combination of thalidomide and cisplatin in an head and neck squamous cell carcinomas model results in an enhanced antiangiogenic activity in vitro and in vivo. Int J Cancer. 2007 Oct 15;121(8):1697-704. doi: 10.1002/ijc.22867.
• [140] Human corneal epithelial cell functional responses to inflammatory agents and their antagonists. Invest Ophthalmol Vis Sci. 1998 Dec;39(13):2562-71.
• [141] Increased inflammasome related gene expression profile in PBMC may facilitate T helper 17 cell induction in multiple sclerosis. Mol Immunol. 2015 Feb;63(2):521-9. doi: 10.1016/j.molimm.2014.10.008.
• [142] Acetylcholine and nicotine stimulate the release of granulocyte-macrophage colony stimulating factor from cultured human bronchial epithelial cells. Naunyn Schmiedebergs Arch Pharmacol. 1998 Apr;357(4):472-5. doi: 10.1007/pl00005195.
• [143] Kaempferol and quercetin stimulate granulocyte-macrophage colony-stimulating factor secretion in human prostate cancer cells. Mol Cell Endocrinol. 2008 Jun 11;287(1-2):57-64. doi: 10.1016/j.mce.2008.01.015. Epub 2008 Feb 3.
• [144] Differential substrate and inhibitory activities of ranitidine and famotidine toward human organic cation transporter 1 (hOCT1; SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3). J Pharmacol Exp Ther. 2005 Dec;315(3):1288-97.
• [145] Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
• [146] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [147] The pregnane X receptor down-regulates organic cation transporter 1 (SLC22A1) in human hepatocytes by competing for ("squelching") SRC-1 coactivator. Br J Pharmacol. 2016 May;173(10):1703-15. doi: 10.1111/bph.13472. Epub 2016 Apr 8.
• [148] Differential gene expression in human hepatocyte cell lines exposed to the antiretroviral agent zidovudine. Arch Toxicol. 2014 Mar;88(3):609-23. doi: 10.1007/s00204-013-1169-3. Epub 2013 Nov 30.
• [149] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [150] Gene expression signatures after ethanol exposure in differentiating embryoid bodies. Toxicol In Vitro. 2018 Feb;46:66-76.
• [151] Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
• [152] Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
• [153] Retinoic acid-induced downmodulation of telomerase activity in human cancer cells. Exp Mol Pathol. 2005 Oct;79(2):108-17.
• [154] Expression profile analysis of human peripheral blood mononuclear cells in response to aspirin. Arch Immunol Ther Exp (Warsz). 2005 Mar-Apr;53(2):151-8.
• [155] Low doses of cisplatin induce gene alterations, cell cycle arrest, and apoptosis in human promyelocytic leukemia cells. Biomark Insights. 2016 Aug 24;11:113-21.
• [156] Copper deprivation enhances the chemosensitivity of pancreatic cancer to rapamycin by mTORC1/2 inhibition. Chem Biol Interact. 2023 Sep 1;382:110546. doi: 10.1016/j.cbi.2023.110546. Epub 2023 Jun 7.